BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30065196)

  • 1. Understanding Ovarian Cancer: iTRAQ-Based Proteomics for Biomarker Discovery.
    Swiatly A; Horala A; Matysiak J; Hajduk J; Nowak-Markwitz E; Kokot ZJ
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30065196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
    Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
    Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.
    Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM
    J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF].
    Zhao Q; Duan W; Wu YM; Qian XH; Deng XH
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):754-8. PubMed ID: 19173805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.
    Wang Q; Li D; Zhang W; Tang B; Li QQ; Li L
    Int J Biol Markers; 2011; 26(4):262-73. PubMed ID: 21928244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative proteome analysis of ovarian cancer tissues using a iTRAQ approach.
    Wang LN; Tong SW; Hu HD; Ye F; Li SL; Ren H; Zhang DZ; Xiang R; Yang YX
    J Cell Biochem; 2012 Dec; 113(12):3762-72. PubMed ID: 22807371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
    Zheng H; Gao Y
    Int J Gynecol Cancer; 2012 Jul; 22(6):1000-5. PubMed ID: 22426406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis.
    Zhan X; Li H; Qian S; Zhan X; Li N
    J Vis Exp; 2019 Nov; (153):. PubMed ID: 31789316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and validation of salivary proteomic signatures for non-invasive detection of ovarian cancer.
    Tajmul M; Parween F; Singh L; Mathur SR; Sharma JB; Kumar S; Sharma DN; Yadav S
    Int J Biol Macromol; 2018 Mar; 108():503-514. PubMed ID: 29222021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors.
    Cymbaluk-Ploska A; Chudecka-Glaz A; Surowiec A; Pius-Sadowska E; Machalinski B; Menkiszak J
    Asian Pac J Cancer Prev; 2016; 17(5):2597-603. PubMed ID: 27268637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
    Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic analysis of serum of women with elevated Ca-125 to differentiate malignant from benign ovarian tumors.
    Li L; Xu Y; Yu CX
    Asian Pac J Cancer Prev; 2012; 13(7):3265-70. PubMed ID: 22994745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker discovery in ovarian cancer.
    Tung CS; Wong KK; Mok SC
    Womens Health (Lond); 2008 Jan; 4():27-40. PubMed ID: 19072449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.
    Swiatly A; Horala A; Hajduk J; Matysiak J; Nowak-Markwitz E; Kokot ZJ
    BMC Cancer; 2017 Jul; 17(1):472. PubMed ID: 28683725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
    Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
    Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array.
    Vathipadiekal V; Wang V; Wei W; Waldron L; Drapkin R; Gillette M; Skates S; Birrer M
    Clin Cancer Res; 2015 Nov; 21(21):4960-9. PubMed ID: 25944803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. iTRAQ technology-based identification of human peripheral serum proteins associated with depression.
    Wang Q; Su X; Jiang X; Dong X; Fan Y; Zhang J; Yu C; Gao W; Shi S; Jiang J; Jiang W; Wei T
    Neuroscience; 2016 Aug; 330():291-325. PubMed ID: 27268281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of ovarian cancer markers in endometriosis favours HE4 over CA125.
    Mckinnon B; Mueller MD; Nirgianakis K; Bersinger NA
    Mol Med Rep; 2015 Oct; 12(4):5179-84. PubMed ID: 26165164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer.
    Wu W; Wang Q; Yin F; Yang Z; Zhang W; Gabra H; Li L
    Int J Oncol; 2016 Oct; 49(4):1651-65. PubMed ID: 27511453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
    Haslene-Hox H; Oveland E; Woie K; Salvesen HB; Wiig H; Tenstad O
    Biochim Biophys Acta; 2013 Nov; 1834(11):2347-59. PubMed ID: 23707566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.